Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordi Remon

Showing results (1-10 of 184) with videos related to

Pageof 19
Sort By:
Translational Lung Cancer Research|July 23, 2021
Immunotherapy in other thoracic malignancies and uncommon populationsJordi Remon, Benjamin Besse
Nature Reviews. Clinical Oncology|October 28, 2021
Adjuvant immunotherapy for NSCLC - does treating earlier mean treating better?Jordi Remon, Benjamin Besse
Future Oncology (London, England)|January 29, 2015
Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitorsNoemi Reguart, Jordi Remon
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 1, 2019
In Response to the Letter by Dr. Yang et al, Immune-Related Adverse Events (irAEs) Predict for Clinical Efficacy: Forcing on Organ-Specific irAEs and the Critical Role of SteroidsBenjamin Besse, Jordi Remon
Current Opinion in Oncology|January 7, 2017
Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancerJordi Remon, Benjamin Besse
ESMO Open|November 16, 2016
Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsJordi Remon, Benjamin Besse
Translational Lung Cancer Research|March 26, 2015
Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patientsMargarita Majem, Jordi Remon
Translational Lung Cancer Research|March 26, 2015
EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: a clue to overcoming resistanceJordi Remon, Margarita Majem
Nature Reviews. Clinical Oncology|March 1, 2020
Upfront osimertinib - winner takes it all?Jordi Remon, Gilberto Lopes
Future Oncology (London, England)|October 10, 2015
AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patientsJordi Remon, David Planchard
Pageof 19

Showing results (1-10 of 184) with videos related to

Sort By:
Pageof 19
Translational Lung Cancer Research|July 23, 2021
Immunotherapy in other thoracic malignancies and uncommon populationsJordi Remon, Benjamin Besse
Nature Reviews. Clinical Oncology|October 28, 2021
Adjuvant immunotherapy for NSCLC - does treating earlier mean treating better?Jordi Remon, Benjamin Besse
Future Oncology (London, England)|January 29, 2015
Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitorsNoemi Reguart, Jordi Remon
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 1, 2019
In Response to the Letter by Dr. Yang et al, Immune-Related Adverse Events (irAEs) Predict for Clinical Efficacy: Forcing on Organ-Specific irAEs and the Critical Role of SteroidsBenjamin Besse, Jordi Remon
Current Opinion in Oncology|January 7, 2017
Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancerJordi Remon, Benjamin Besse
ESMO Open|November 16, 2016
Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsJordi Remon, Benjamin Besse
Translational Lung Cancer Research|March 26, 2015
Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patientsMargarita Majem, Jordi Remon
Translational Lung Cancer Research|March 26, 2015
EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: a clue to overcoming resistanceJordi Remon, Margarita Majem
Nature Reviews. Clinical Oncology|March 1, 2020
Upfront osimertinib - winner takes it all?Jordi Remon, Gilberto Lopes
Future Oncology (London, England)|October 10, 2015
AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patientsJordi Remon, David Planchard
Pageof 19